A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report - Concepedia

Concepedia

Publication | Open Access

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report

DOI Full Paper Access

61

Citations

37

References

2015

Year

E. Anders Kolb, Valerie B. Sampson, Deborah L. Stabley, Alexa E. Walter, Katia Sol‐Church, Timothy P. Cripe, Pooja Hingorani, Charlotte H. Ahern, Brenda J. Weigel, James A. Zwiebel,

Pediatric Blood & Cancer

Abstract

Reolysin at a dose of 5 × 10(8) TCID50 /kg daily for 5 days was well tolerated in children alone and in combination with oral cyclophosphamide. Virus was cleared rapidly from the serum and shedding in stool and saliva was not detectable.

References

	Year	Citations

Page 1